These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35813248)

  • 1. External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort.
    Chandra Engel J; Palsdottir T; Ankerst D; Remmers S; Mortezavi A; Chellappa V; Egevad L; Grönberg H; Eklund M; Nordström T
    Eur Urol Open Sci; 2022 Jul; 41():1-7. PubMed ID: 35813248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
    Palsdottir T; Grönberg H; Hilmisson A; Eklund M; Nordström T; Vigneswaran HT
    Eur Urol Focus; 2023 May; 9(3):455-462. PubMed ID: 36522257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
    Patel HD; Koehne EL; Shea SM; Fang AM; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
    BJU Int; 2023 Feb; 131(2):227-235. PubMed ID: 35733400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating PHI in decision making: external validation of the Rotterdam risk calculators for detection of prostate cancer.
    Rius Bilbao L; Aguirre Larracoechea U; Valladares Gomez C; Remmers S; Mar Medina C;
    World J Urol; 2024 Mar; 42(1):141. PubMed ID: 38478041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data.
    Remmers S; Kasivisvanathan V; Verbeek JFM; Moore CM; Roobol MJ;
    Eur Urol Open Sci; 2022 Feb; 36():1-8. PubMed ID: 35098168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External validation of the Rotterdam prostate cancer risk calculator within a high-risk Dutch clinical cohort.
    Hagens MJ; Stelwagen PJ; Veerman H; Rynja SP; Smeenge M; van der Noort V; Roeleveld TA; van Kesteren J; Remmers S; Roobol MJ; van Leeuwen PJ; van der Poel HG
    World J Urol; 2023 Jan; 41(1):13-18. PubMed ID: 36245015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer.
    Morote J; Borque-Fernando Á; Triquell M; Campistol M; Servian P; Abascal JM; Planas J; Méndez O; Esteban LM; Trilla E
    Eur Urol Open Sci; 2023 Jul; 53():46-54. PubMed ID: 37441350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Multiparametric Magnetic Resonance of Prostate Outperform Risk Calculators in Predicting Prostate Cancer in Biopsy Naïve Patients?
    Falagario UG; Silecchia G; Bruno SM; Di Nauta M; Auciello M; Sanguedolce F; Milillo P; Macarini L; Selvaggio O; Carrieri G; Cormio L
    Front Oncol; 2020; 10():603384. PubMed ID: 33489907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators.
    Mortezavi A; Palsdottir T; Eklund M; Chellappa V; Murugan SK; Saba K; Ankerst DP; Haug ES; Nordström T
    Eur Urol Focus; 2021 May; 7(3):546-553. PubMed ID: 32451315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Magnetic Resonance Imaging-Based Risk Calculators to Predict Prostate Cancer Risk.
    Patel HD; Remmers S; Ellis JL; Li EV; Roobol MJ; Fang AM; Davik P; Rais-Bahrami S; Murphy AB; Ross AE; Gupta GN
    JAMA Netw Open; 2024 Mar; 7(3):e241516. PubMed ID: 38451522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of magnetic resonance imaging-based prostate cancer risk calculators and decision strategies in two large European medical centres.
    Davik P; Remmers S; Elschot M; Roobol MJ; Bathen TF; Bertilsson H
    BJU Int; 2024 Mar; 133(3):278-288. PubMed ID: 37607322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort.
    Carbunaru S; Nettey OS; Gogana P; Helenowski IB; Jovanovic B; Ruden M; Hollowell CMP; Sharifi R; Kittles RA; Schaeffer E; Gann P; Murphy AB
    BMC Urol; 2019 Nov; 19(1):121. PubMed ID: 31771578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy.
    Wei G; Kelly BD; Timm B; Perera M; Lundon DJ; Jack G; Bolton DM
    BJUI Compass; 2021 May; 2(3):194-201. PubMed ID: 35475133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. External Validation of Stockholm3 in a Retrospective German Clinical Cohort.
    Tilki D; Rejek N; Nohe F; Haese A; Graefen M; Thederan I
    Eur Urol Focus; 2024 Aug; ():. PubMed ID: 39112137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator.
    Parekh S; Ratnani P; Falagario U; Lundon D; Kewlani D; Nasri J; Dovey Z; Stroumbakis D; Ranti D; Grauer R; Sobotka S; Pedraza A; Wagaskar V; Mistry L; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Martini A; Picker W; Haug E; Cormio L; Nordström T; Briganti A; Boström PJ; Carrieri G; Haines K; Gorin MA; Wiklund P; Menon M; Tewari A
    Eur Urol Open Sci; 2022 Jul; 41():45-54. PubMed ID: 35813258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome.
    Pereira-Azevedo N; Verbeek JFM; Nieboer D; Bangma CH; Roobol MJ
    Transl Androl Urol; 2018 Feb; 7(1):18-26. PubMed ID: 29594016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
    Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
    Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification.
    Davik P; Remmers S; Elschot M; Roobol MJ; Bathen TF; Bertilsson H
    BJUI Compass; 2022 Sep; 3(5):344-353. PubMed ID: 35950035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator.
    van Riel LAMJG; Jager A; Meijer D; Postema AW; Smit RS; Vis AN; de Reijke TM; Beerlage HP; Oddens JR
    Ther Adv Urol; 2022; 14():17562872221088536. PubMed ID: 35356754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
    Doan P; Graham P; Lahoud J; Remmers S; Roobol MJ; Kim L; Patel MI
    BJU Int; 2021 Dec; 128 Suppl 3():36-44. PubMed ID: 34374190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.